Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | Fund Letter | David BastianKingdom Capital Advisors | Superior Industries $SUP• NYSE | -- | Long SUP (Superior Industries International, Inc.) The manager remains committed to Superior Industries despite tariff headwinds, expecting eventual adjustments and exemptions due to the administration's consumer cost focus. The company is... | BULL | View Pitch → |
| Aug 21, 2026 | Fund Letter | David BastianKingdom Capital Advisors | Superior Industries $SUP• NYSE | -- | Long SUP (Superior Industries International, Inc.) Superior Industries is generating positive cash flow and expanding its margins despite low US auto inventories and production lags. Furthermore, its inroads... | BULL | View Pitch → |
| Aug 21, 2026 | Fund Letter | David BastianKingdom Capital Advisors | Superior Industries $SUP• NYSE | -- | Long SUP (Superior Industries) Despite recent stock price declines, the company's manufacturing presence in Mexico is shielded from potential tariff impacts since the vast majority of the US wheel market relies on imports. The company's robust... | BULL | View Pitch → |
| Jan 8, 2026 | Fund Letter | Matthew Fine, CFA and Jason Wolf, CFAThird Avenue Small Cap Value Fund | Supernus Pharmaceuticals $SUPN• NASDAQ | PharmaceuticalsPharmaceuticals | Third Avenue Small-Cap Value Fund 2025 Q2 (SUPN) Supernus Pharmaceuticals announced an opportunistic acquisition of Sage Therapeutics, which will be funded by Supernus' $460 million net cash balance. A.... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.